期刊文献+

恶性黑素瘤和普通痣细胞痣细胞外信号调节激酶途径相关蛋白的研究 被引量:2

The Study of ERK Pathway Related Protein Expression in Malignant Melanoma and Ordinary Nevi
原文传递
导出
摘要 目的探讨恶性黑素瘤(MM)和普通痣细胞痣细胞外信号调节激酶(ERK)途径相关蛋白ERK1和ERK2以及细胞周期素D1(CyclinD1)蛋白的表达情况,分析这3种蛋白与MM的临床病理关系。方法采用免疫组化SP法对30例MM和13例普通痣细胞痣中ERK1、ERK2和CyclinD1蛋白的表达进行检测,并进行临床病理相关性分析。结果ERK1、ERK2和CyclinD1在MM组织中表达较普通痣细胞痣组织明显升高(P<0.01),ERK1、ERK2和CyclinD1与MM的Clark分级和Breslow厚度无明显相关性,ERK1和ERK2与CyclinD1在MM组织中表达显著相关。结论MM中ERK途径得到了过度激活,并可能促使CyclinD1表达增加,因此它们在MM的发病机制中可能起到一定作用,而它们在普通痣细胞中仅在A型痣细胞表达增加。 Objective To investigate the roles of extracellular signal-regulated kinase (ERK)1, ERK2 and Cyclin D1 proteins in malignant melanoma (MM) and ordinary nevus. Methods By SP immunohistochemical method, the expression of ERK1, ERK2 and Cyclin D1 proteins was detected in 30 cases of MM and 13 cases of ordinary nevi. Results The expression of ERK1, ERK2 and Cyclin D1 proteins was higher in MMs than that in ordinary nevi (P < 0.01). The expression of ERK1, ERK2 and Cyclin D1 was not correlated with Clark level and Breslow thickness. The expression of ERK1 and ERK2 was correlated with that of Cyclin D1. Conclusions ERK pathway is activated in MM and may result in Cyclin D1 over-expression, while in ordinary nevi, only expression of type A nevus cell is increased.
机构地区 中国医学科学院
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2004年第9期506-508,共3页 Chinese Journal of Dermatology
关键词 ERK MM 痣细胞 表达 相关蛋白 胞外信号调节激酶 恶性黑素瘤 Melanoma Nevus Mitogen-activated protein kinases Cyclin D1
  • 相关文献

参考文献5

  • 1Sauter ER, Yeo UC, von Stemm A, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res, 2002, 62: 3200-3206.
  • 2Slominski A, Wortsman J, Carlson AJ, et al. Malignant melanoma.Arch Pathol Lab Med, 2001, 125: 1295-1306.
  • 3Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature, 2002, 417: 949-954.
  • 4Satyamoorthy K, Li G, Gerrero MR, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res, 2003, 63: 756-759.
  • 5Balch CM, Buzaid AC, Atkins MB, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer, 2000, 88: 1484-1491.

同被引文献13

  • 1Vorburger SA, Pataer A, Swisher SG, et al. Genetically targeted cancer therapy: tumor destruction by PKR activation. Am J Pharmacogenomics, 2004, 4: 189-198.
  • 2Haines GK, Cajulis R, Hayden R, et al. Expression of the doublestranded RNA-dependent protein kinase (p68) in human breast tissues. Tumour Biol, 1996, 17: 5-12.
  • 3Shir A, Levitzki A. Inhibition of glioma growth by tumor-specific activation of double-stranded RNA-dependent protein kinase PKR. Nat Biotechnol, 2002, 20: 895-900.
  • 4Benkirane M, Neuveut C, Chun RF, et al. Oncogenic potential of TAR RNA binding protein TRBP and its regulatory interaction with RNA-dependent protein kinase PKR. EMBO J, 1997, 16:611-624.
  • 5McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimericanti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: halfof patients respond to a four-dose treatment program[J]. Clin Oncol, 1998,16: 2825-2833.
  • 6Jackson H, Bacon L, Pedley RB, et al. Antigen specificity and tumortargeting efficiency of human carcinoembryonic antigen-specific scFv andaffinity-matured derivatives[J]. Br J Cancer, 1998, 78(2): 181-188.
  • 7Shawler DL, Bartholomew RM, Smith LM, et al. Human immuneresponse tomultiple injections of murine monoclonal IgG[J]. Immunol, 1985, 135(2):1530-1535.
  • 8Sblattero D, Bradbury A. Exploiting recombination in single bacteriato make large phage antibody libraries[J]. Nat Biotechnol, 2000, 18:74-80.
  • 9宋丽华,宋现让.乳腺癌治疗新药Herceptin[J].国外医学(肿瘤学分册),2002,29(1):39-43. 被引量:16
  • 10王建力,陈莉,王桂兰,曹晓蕾.p63、增殖细胞核抗原和表皮生长因子受体在皮肤鳞状细胞癌中的表达[J].中华皮肤科杂志,2002,35(2):143-145. 被引量:9

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部